BioPharmSignal logoBioPharmSignal

Biotech News

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

Aprea Therapeutics (APRE)Aprea TherapeuticsFinancing

Funding will support ongoing development of APR-1051, including expansion into selected patient populations where WEE1 mechanism is well suited DOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision

Related news

APREAprea Therapeutics2026-07-30 12:00 EST

Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026

APREAprea Therapeutics2026-06-01 12:00 EST

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

SNDXSyndax Pharmaceuticals2026-06-04 11:00 EST

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

ELVNEnliven Therapeutics2026-06-15 20:40 EST

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

ELVNEnliven Therapeutics2026-06-12 02:39 EST

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

ERASErasca2026-07-15 20:01 EST

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

ERASErasca2026-07-13 20:19 EST

Erasca Announces Proposed Public Offering of $500 Million of Common Stock

IDYAIDEAYA Biosciences2026-06-10 20:05 EST

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

LEGNLegend Biotech Corporation2026-06-18 01:21 EST

Legend Biotech Corporation Announces Pricing of Public Offering

LEGNLegend Biotech Corporation2026-06-17 20:29 EST

Legend Biotech Corporation Announces Proposed Public Offering

View all latest news

Aprea Therapeutics

DNA Damage Response Oncology Company Aprea Therapeutics develops precision medicines targeting vulnerabilities in cancer-cell DNA replication and repair. APR-1051 APR-1051 is a selective WEE1 inhibitor being evaluated in the Phase 1/2 ACESOT-1051 study for advanced solid tumors. Biomarker-Directed Expansion Development is expanding in...

Recent company news

APREAprea Therapeutics2026-07-30 12:00 EST

Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026

APREAprea Therapeutics2026-06-01 12:00 EST

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

APREAprea Therapeutics2026-05-13 10:30 EST

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

APREAprea Therapeutics2026-04-21 14:15 EST

Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

APREAprea Therapeutics2026-04-01 12:31 EST

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

Stock data

Close
0.63 USD
Market cap
9.46M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States